Sunlight Research((TM)) - The Source for Patent Analysis today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio.
The Report analyzes the patent claims coverage of 38 US patents owned or controlled by Amgen (Nasdaq: AMGN), and explains how those patents do or do not cover the corresponding technology used in their commercial product Epogen. The technology focuses on recombinant erythropoietin, pharmaceutical compositions comprising erythropoietin, human erythropoietin gene sequences and the combination of erythropoietin with other proteins, such as stem cell factor.
Daniel A. Halpern, President of Sunlight Research, LLC remarked, "Anyone interested in the development, manufacture or use of biologics in the US should get a copy of our report. EvaluatePharma has predicted that, 'six of the top ten drugs in 2014 will be biologics.' The total projected annual sales of 'the six' are estimated to be in excess of $ 50 billion." Halpern added that, "the development of follow-on biologics will also depend upon the patent protection of well known biologicals, such as EPO."
Sunlight's Amgen EPO patents report includes a detailed breakdown of claim limitations including composition limitations, therapy limitations, DNA sequence limitations, and biological activity limitations relating to Amgen's Epogen drug. The report provides insights into strengths and weaknesses of Amgen's patent coverage, and opportunities for adjacent or competing products.